Relay Therapeutics Inc (NASDAQ: RLAY) on Monday, soared 3.71% from the previous trading day, before settling in for the closing price of $3.5. Within the past 52 weeks, RLAY’s price has moved between $1.77 and $10.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -23.05%. The company achieved an average annual earnings per share of 20.84%. With a float of $129.32 million, this company’s outstanding shares have now reached $170.48 million.
The extent of productivity of a business whose workforce counts for 261 workers is very important to gauge. In terms of profitability, gross margin is -12.15%, operating margin of -4927.05%, and the pretax margin is -4341.53%.
Relay Therapeutics Inc (RLAY) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Relay Therapeutics Inc is 24.57%, while institutional ownership is 84.21%. The most recent insider transaction that took place on Jul 09 ’25, was worth 219,123. In this transaction President and CEO of this company sold 61,379 shares at a rate of $3.57, taking the stock ownership to the 765,288 shares. Before that another transaction happened on Apr 30 ’25, when Company’s insider sold 10,739 for $3.00, making the entire transaction worth $32,217. This insider now owns 390,081 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 20.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.39% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Relay Therapeutics Inc (RLAY) is currently performing well based on its current performance indicators. A quick ratio of 19.96 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 81.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.85 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
The latest stats from [Relay Therapeutics Inc, RLAY] show that its last 5-days average volume of 2.67 million was superior to 2.22 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 31.62%.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 86.92%, which indicates a significant increase from 56.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was lower than the 0.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.26, while its 200-day Moving Average is $4.09.
